Retatrutide Suhoor Protocol — Ramadan UAE Researcher Guide

Why the UAE Research Community Cares About Ramadan and Triple Agonism

The UAE hosts one of the highest concentrations of research-oriented professionals tracking body composition, metabolic biomarkers, and peptide pharmacodynamics in the Gulf. Dubai, Abu Dhabi, Sharjah, and the wider Emirates are home to a rapidly growing cohort of independent labs, private wellness research facilities, and corporate health tracking programmes that treat Ramadan not as a pause in protocols but as one of the most data-rich natural experiments available — a societally synchronised 30-day intermittent fasting cycle across millions of subjects.

Retatrutide, the triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, is the most potent metabolic research peptide currently available to UAE-based researchers. Its phase 2 efficacy data, published by Jastreboff et al. in the New England Journal of Medicine (2023), documented mean body weight reductions of up to 17.5% at 24 weeks — a result that eclipsed any prior injectable metabolic compound in published trial data. The ongoing Eli Lilly TRIUMPH phase 3 programme is expected to confirm and extend those findings. For researchers in Dubai and Abu Dhabi planning metabolic studies, this is the compound that warrants the most careful protocol design.

The intersection of retatrutide and Ramadan is not merely logistical. The compound's glucagon receptor agonism — absent in dual GLP-1/GIP agonists like tirzepatide — activates hepatic glucose output and promotes fatty acid oxidation even in a fasted state. During a Ramadan fasting window in Dubai (typically fajr around 05:00 GST to maghrib around 18:30 GST), subjects are already running on elevated glucagon and ketone substrate. Layering a triple agonist onto that fasted physiology creates research observations that a standard three-meal protocol simply cannot replicate. This guide is the reference document UAE researchers should have in hand before Ramadan 2027 — and a useful retrospective for teams reviewing Ramadan 2026 data now.

Everything that follows is framed for research-use contexts only. No content on this page constitutes medical advice. All references to administration, dosing ranges, and timing apply exclusively to controlled laboratory and in-vivo research frameworks.

Retatrutide Mechanism: What the Triple Agonist Does That Matters in Fasting-State Research

Most peptide researchers in UAE labs are already familiar with GLP-1 receptor agonism from prior work with semaglutide analogues. Retatrutide adds two additional axes that change the research calculus substantially:

• GLP-1R (glucagon-like peptide-1 receptor): Stimulates insulin secretion in a glucose-dependent manner, slows gastric emptying, and suppresses appetite signalling via hypothalamic pathways. This is the axis most relevant to iftar caloric intake observations.
• GIPR (glucose-dependent insulinotropic polypeptide receptor): Amplifies post-prandial insulin response and is implicated in adipocyte lipid turnover. Most active in the post-suhoor or post-iftar window when nutrient absorption peaks.
• GCGR (glucagon receptor): Promotes hepatic glucose output, increases thermogenesis, and drives lipolysis. This receptor remains relevant even during the fasting window when caloric input is zero — making it the dominant pharmacodynamic signal during the 13-hour Ramadan fast.

The glucagon axis is the decisive differentiator for fasting-state research. A GLP-1-only compound goes effectively quiet when a subject is fasted and not secreting insulin. Retatrutide's GCGR component remains active, potentially amplifying the already-elevated lipolytic state of Ramadan fasting. UAE researchers tracking fat mass, visceral adiposity markers, and fasting lipid panels during Ramadan cycles have a compound that does not simply pause between eating windows — it continues to engage a receptor whose natural ligand is elevated throughout the daylight fast.

The Jastreboff et al. 2023 NEJM trial documented dose-response data across five arms (1mg, 2mg, 4mg, 8mg, and 12mg weekly). The 2mg, 4mg, and 8mg ranges are the most commonly referenced in UAE research protocols because they align with practical vial yield from the 5mg and 10mg formats stocked at REVIVE LAB UAE, and because published phase 2 data covers their effects with granularity. The 12mg arm is beyond what REVIVE LAB UAE currently stocks, and researchers should not attempt to extrapolate upward from available vial formats.

The Suhoor and Iftar Windows: A Protocol Timing Map for Dubai Researchers

Designing a Ramadan retatrutide protocol requires anchoring to actual GST timing. The table below reflects approximate times for Dubai during Ramadan 2026 (mid-February to mid-March). Times shift slightly across the 30-day cycle as sunrise advances.

For researchers choosing injection timing, two arms are worth pre-specifying at the protocol design stage and should not be mixed within the same cohort without stratification:

• Suhoor-timed injection: Administered approximately 60 minutes before fajr. The compound's early pharmacodynamic window (first 24–48 hours) coincides with the long daylight fast. Gastric emptying effects are less observable because no food is consumed during this window. Lipolytic markers from GCGR agonism may be most pronounced in this arm due to the fasted-state synergy.
• Iftar-timed injection: Administered at the time of fast-breaking. GLP-1R-mediated appetite suppression engages precisely at the moment the subject re-introduces food, creating a measurable ceiling on iftar caloric intake. Post-prandial insulin and lipid markers in the 2–4 hours after iftar are the primary signal window in this arm.

UAE researchers who ran comparative arms through Ramadan 2026 noted qualitatively different gastric motility and appetite observation profiles between the two timing strategies. Neither is inherently superior — the right choice depends on whether the research hypothesis centres on fasting-state metabolism (suhoor arm) or re-feeding behaviour and post-prandial suppression (iftar arm).

Research Titration Reference Ranges: What the Phase 2 Data Actually Shows

UAE research protocols should anchor to published data wherever possible. The Jastreboff et al. 2023 NEJM trial remains the primary reference for retatrutide dose-response relationships in a weekly subcutaneous injection model. The following table maps the published trial arms against practical vial yield from REVIVE LAB UAE's 5mg and 10mg formats.

The practical takeaway for UAE researchers: if the protocol runs a conservative titration starting at 2mg and escalating to 4mg across a Ramadan cycle (four weekly injections), two 10mg vials cover the sequence cleanly. A 30-day Ramadan protocol at a fixed 4mg weekly research dose requires a minimum of two 10mg vials per subject; ordering three per subject provides a buffer against reconstitution error or a missed injection requiring a make-up dose. For researchers at 8mg, the 10mg vial covers one weekly injection with 2mg remaining — plan accordingly.

The 5mg vial is best suited to researchers working at the 2mg reference range (2.5 doses per vial), to those running shorter observation windows, or to those new to retatrutide research who want to start with a conservative stock commitment before scaling to the 10mg format. REVIVE LAB UAE stocks both formats in stock in UAE year-round, with no minimum order beyond a single vial.

Reconstitution and Cold-Chain Logistics in UAE Summer

This section is operational rather than theoretical, and it matters more in the UAE than in almost any other research geography. The UAE summer (May through September) sees outdoor temperatures exceeding 42°C in Dubai, Abu Dhabi, and Sharjah — conditions that destroy improperly handled lyophilised peptides within hours of cold-chain failure.

Reconstitution Protocol

Retatrutide vials from REVIVE LAB UAE arrive as lyophilised (freeze-dried) powder. Reconstitution requires bacteriostatic water added slowly via syringe along the vial wall — not injected directly onto the powder cake. Do not shake. Swirl gently until fully dissolved. Reconstituted vials should be stored at 2–8°C (standard laboratory refrigerator) and used within 28 days. Do not freeze reconstituted stock. Label each vial with reconstitution date and volume per draw.

UAE-Specific Storage Considerations

• Lyophilised (unreconstituted) vials store at −20°C indefinitely within REVIVE LAB UAE's stated shelf life. In the UAE summer, reconstitute only what you need for the immediate protocol cycle — do not reconstitute a season's supply in advance.
• If your lab or facility is in Business Bay, the Marina, JBR, or Palm Jumeirah towers, standard building HVAC keeps interior temperatures in safe range. The risk window is transit — from delivery to your door. REVIVE LAB UAE mitigates this with insulated gel-pack packaging designed for UAE summer conditions.
• For researchers in Abu Dhabi, Sharjah, or Fujairah receiving next-day deliveries, the insulated packaging maintains cold-chain integrity through standard UAE courier transit times. Inspect the gel pack on receipt — if it has fully liquefied without any residual cold, flag the shipment before opening the inner vial packaging.
• Do not store reconstituted vials in a household refrigerator shared with food in high-traffic use. Temperature fluctuations from door-opening are a degradation risk at the 28-day ceiling.

Discreet Delivery and Lab Address Considerations

All REVIVE LAB UAE shipments use plain, unmarked outer packaging with no brand name, product description, or lab identifier on the exterior. Inner packaging is insulated and labelled with a generic reference code only. Researchers at corporate facilities in DIFC or Business Bay who prefer to receive deliveries at a residential address (Dubai Marina, Downtown, JBR) can specify an alternate address at checkout — this is common practice and fully supported.

Practical Protocol Checklist: Planning a Ramadan Retatrutide Research Cycle

The following checklist is adapted from research protocol frameworks observed at UAE-based independent metabolic research teams through Ramadan 2026. It applies equally to retrospective data review and to preparation for Ramadan 2027.

Pre-Ramadan (Two to Three Weeks Out)

• Confirm vial stock is in hand. Order from REVIVE LAB UAE at least 48 hours before Ramadan starts — retatrutide same-day delivery is available in Dubai, but forward-stocking avoids any friction in the protocol's first week when demand from regional researchers spikes.
• Establish baseline metabolic markers for each research subject: fasting glucose, fasting insulin, lipid panel (total cholesterol, LDL, HDL, triglycerides), body weight, and waist circumference at minimum.
• Decide injection timing arm — suhoor or iftar — and randomise if running a comparative cohort. Document this in the protocol before day one.
• Set up a data logging template that captures: injection timestamp (GST), suhoor meal composition and estimated calories, iftar meal composition and estimated calories, Tarawih activity Y/N, body weight at fixed time (recommended: pre-suhoor, post-wudu, same scale), and any gastric symptom observations.
• Confirm bacteriostatic water and insulin syringes (appropriate gauge for subcutaneous research administration) are in stock at the lab or research site.

During Ramadan (Weekly Protocol Rhythm)

• Administer weekly injection at the pre-specified timing arm. Log timestamp, dose in mg, and vial batch reference.
• Log suhoor and iftar composition for injection day and the two days following — this captures the primary pharmacodynamic observation window.
• Record gastric motility observations (nausea, delayed satiety, reduced appetite) for the 48-hour post-injection window. These are not adverse events to suppress — they are research signals to quantify.
• Weigh subjects at the same point in the daily cycle each week. Pre-suhoor is the most reproducible: dehydration state is consistent, and no food has been consumed since the prior night's iftar.
• Re-order before your last vial is opened. REVIVE LAB UAE offers retatrutide 24h delivery Dubai as a backstop, but maintaining a one-vial buffer eliminates any protocol gap risk.

Post-Ramadan Data Analysis

• Repeat all baseline markers at day 30 post-Ramadan. Do not conflate Ramadan caloric restriction with compound effect — the control arm comparison is essential.
• Compare weight trajectory against the Jastreboff et al. 2023 24-week curve for the relevant dose arm, adjusted for the shorter 30-day Ramadan observation window.
• If running suhoor vs. iftar timing arms, compare gastric symptom logs and weight change separately before pooling cohort data.

Common Protocol Errors UAE Researchers Make with Retatrutide During Ramadan

Experienced UAE peptide research teams have flagged the following as the most common and consequential protocol errors in Ramadan-cycle retatrutide studies. Avoiding these in the design phase is far easier than correcting them in the analysis phase.

• Attributing all weight loss to the compound: Ramadan independently reduces total daily caloric intake in most subjects — often by 15 to 30 percent from non-Ramadan baseline. Without a non-peptide Ramadan control arm or a pre-Ramadan baseline comparison, separating compound effect from fasting effect is not methodologically defensible.
• Inconsistent weigh-in timing: Post-iftar weigh-ins are confounded by fluid intake from breaking fast. Pre-suhoor weigh-ins at a consistent time relative to the last fluid intake are the only reproducible measurement point in a Ramadan calendar.
• Under-ordering vials and creating protocol gaps: A 30-day Ramadan cycle with weekly injections requires four injection points. Order five to six vials per subject to absorb reconstitution error, a spillage, or a courier delay. REVIVE LAB UAE has retatrutide in stock UAE consistently, but a one-vial buffer is basic protocol hygiene.
• Failing to log Tarawih activity: Tarawih prayers (45 to 90 minutes of moderate ambulation and standing, post-iftar, typically 20:30 to 22:00 GST) represent a non-trivial energy expenditure that varies between subjects and between Ramadan days. If body composition is a primary endpoint, Tarawih Y/N and approximate duration must be logged.
• Mixing timing arms within the same cohort: Some researchers switch subjects from suhoor-timing to iftar-timing mid-protocol when logistical issues arise. This creates a within-subject confounder that makes the dataset nearly uninterpretable. Pre-specify timing arm and treat deviations as protocol violations, not as flexible adjustments.
• Ignoring gastric symptoms as noise: GLP-1R agonist-associated nausea, early satiety, and reduced appetite at iftar are primary pharmacodynamic signals in this research context. Researchers who dismiss them as participant complaints and do not log them systematically are discarding data that correlates with dose arm, injection timing, and meal composition.

Ordering Retatrutide in the UAE: REVIVE LAB UAE Supply and Logistics

REVIVE LAB UAE is the UAE-native research peptide supplier with the most consistent year-round stock of retatrutide 5mg and 10mg vials. For researchers who have previously sourced from international suppliers and navigated customs uncertainty, UAE-domestic supply eliminates that variable entirely. Here is the full logistics picture:

• Website: revivelab.ae/buy-retatrutide-uae/ — select vial size and quantity, enter a UAE delivery address, confirm order.
• Same-day delivery Dubai: Orders placed before 14:00 GST are dispatched same day to Dubai addresses — JBR, Marina, Business Bay, Downtown, DIFC, Palm Jumeirah, Al Barsha, Jumeirah Village Circle, and surrounding areas.
• Next-day delivery: Abu Dhabi, Sharjah, Ajman, Fujairah, Umm Al Quwain, and Ras Al Khaimah receive next-day delivery via registered courier.
• Discreet packaging: Plain, unmarked outer boxes. No brand name, product name, or peptide reference on the exterior. Inner packaging maintains cold-chain with insulated liners and gel packs. Standard for all orders.
• Payment options: AED bank transfer, cash on delivery Dubai (no upfront payment required for Dubai addresses), and Binance Pay USDT TRC20 (5% pre-pay discount applied automatically at checkout).
• Minimum order: Single vial. Bulk research orders of 10 or more vials qualify for institutional volume pricing — contact via WhatsApp for a quote before placing a large order.

For researchers at DIFC or Business Bay labs who are mid-protocol and need a rapid resupply, same-day delivery means no protocol interruption. This is a material operational advantage over international suppliers, where customs processing alone can introduce 10 to 14 day delays that break a tightly scheduled titration sequence.

FAQ

Where can I buy retatrutide in the UAE?

REVIVE LAB UAE stocks retatrutide 5mg and 10mg lyophilised vials for laboratory research use, available at revivelab.ae/buy-retatrutide-uae/. Orders placed before 14:00 GST receive same-day delivery within Dubai (JBR, Marina, Business Bay, Downtown, DIFC, Palm Jumeirah). Abu Dhabi, Sharjah, Ajman, Fujairah, and all other UAE emirates receive next-day delivery. Cold-chain packaging and discreet outer packaging are standard on every shipment. Retatrutide is not available at UAE pharmacies — REVIVE LAB UAE is the primary UAE-domestic research supply source.

Does REVIVE LAB UAE offer same-day or 24h delivery in Dubai?

Yes. Orders placed before 14:00 GST qualify for same-day delivery to Dubai addresses. All other UAE emirate deliveries arrive next day. Every order ships with cold-chain gel-pack packaging and unmarked outer boxes. Cash on delivery is available for Dubai orders — no upfront transfer required. For researchers in Abu Dhabi or Sharjah who need rapid resupply, the next-day window is reliable enough to use as a one-vial buffer strategy rather than holding large standing stock.

What vial sizes of retatrutide does REVIVE LAB UAE carry, and what research titration ranges do they cover?

REVIVE LAB UAE carries retatrutide in 5mg and 10mg lyophilised vials. The 10mg vial covers five weekly injections at the 2mg research reference range, two weeks at 4mg, or one injection at 8mg with residual. The 5mg vial is suited to 2mg titration phases or shorter observation windows. These ranges map directly to the Jastreboff et al. 2023 NEJM phase 2 trial arms. Payment options include AED bank transfer, cash on delivery (Dubai), and Binance Pay USDT TRC20 (5% pre-pay discount). Single-vial orders are welcome; bulk institutional pricing is available via WhatsApp.